Centessa Pharmaceuticals plc
CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which iā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$39.76
Price-0.13%
-$0.05
1Y
Price
Market Cap
$6.152b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-66.7%
3y CAGR-50.0%
5y CAGREarnings
-$250.638m
-26.9%
1y CAGR-22.2%
3y CAGR-9.1%
5y CAGREPS
-$1.78
-21.9%
1y CAGR-8.0%
3y CAGR+2.0%
5y CAGRBook Value
$487.348m
$641.763m
Assets$154.415m
Liabilities$7.372m
DebtDebt to Assets
1.2%
-
Debt to EBITDAFree Cash Flow
-$209.166m
-7.7%
1y CAGR-11.0%
3y CAGR-3.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company